These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 20334824)

  • 41. Contrast agent nephropathy.
    Nicol P; Axelson C
    Eur Heart J; 2004 Aug; 25(15):1369; discussion 1369-70. PubMed ID: 15288173
    [No Abstract]   [Full Text] [Related]  

  • 42. N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials.
    Zagler A; Azadpour M; Mercado C; Hennekens CH
    Am Heart J; 2006 Jan; 151(1):140-5. PubMed ID: 16368307
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Contrast media nephropathy--how to diagnose and how to prevent?
    Solomon R
    Nephrol Dial Transplant; 2007 Jul; 22(7):1812-5. PubMed ID: 17449491
    [No Abstract]   [Full Text] [Related]  

  • 44. N-acetylcysteine in the prevention of contrast-induced nephropathy: publication bias perpetuated by meta-analyses.
    Vaitkus PT; Brar C
    Am Heart J; 2007 Feb; 153(2):275-80. PubMed ID: 17239689
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of N-acetylcysteine and aminophylline in preventing contrast-induced nephropathy.
    Kinbara T; Hayano T; Ohtani N; Furutani Y; Moritani K; Matsuzaki M
    J Cardiol; 2010 Mar; 55(2):174-9. PubMed ID: 20206069
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT).
    ACT Investigators
    Circulation; 2011 Sep; 124(11):1250-9. PubMed ID: 21859972
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Contrast medium-induced nephropathy: strategies for prevention.
    Massicotte A
    Pharmacotherapy; 2008 Sep; 28(9):1140-50. PubMed ID: 18752385
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High-dose N-acetylcysteine for the prevention of contrast-induced nephropathy.
    Trivedi H; Daram S; Szabo A; Bartorelli AL; Marenzi G
    Am J Med; 2009 Sep; 122(9):874.e9-15. PubMed ID: 19699385
    [TBL] [Abstract][Full Text] [Related]  

  • 49. N-acetylcysteine versus N-acetylcysteine + theophylline for the prevention of contrast nephropathy.
    Baskurt M; Okcun B; Abaci O; Dogan GM; Kilickesmez K; Ozkan AA; Ersanli M; Gurmen T
    Eur J Clin Invest; 2009 Sep; 39(9):793-9. PubMed ID: 19500141
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial.
    Ozcan EE; Guneri S; Akdeniz B; Akyildiz IZ; Senaslan O; Baris N; Aslan O; Badak O
    Am Heart J; 2007 Sep; 154(3):539-44. PubMed ID: 17719303
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cystatin C and creatinine as markers for radiocontrast-induced nephropathy in patients treated with N-acetylcysteine.
    Merkle M; Sauter M; Argirov M; Wörnle M
    Ren Fail; 2010 Jan; 32(1):85-90. PubMed ID: 20113272
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of N-acetylcysteine on cystatin C-based renal function after elective coronary angiography (ENABLE Study): a prospective, randomized trial.
    Kim BJ; Sung KC; Kim BS; Kang JH; Lee KB; Kim H; Lee MH
    Int J Cardiol; 2010 Feb; 138(3):239-45. PubMed ID: 18793808
    [TBL] [Abstract][Full Text] [Related]  

  • 53. N-acetylcysteine in the prevention of radiocontrast-induced nephropathy: clinical trials and end points.
    Hoffmann U; Banas B; Fischereder M; Krämer BK
    Kidney Blood Press Res; 2004; 27(3):161-6. PubMed ID: 15256811
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy.
    Allaqaband S; Tumuluri R; Malik AM; Gupta A; Volkert P; Shalev Y; Bajwa TK
    Catheter Cardiovasc Interv; 2002 Nov; 57(3):279-83. PubMed ID: 12410497
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.
    Oldemeyer JB; Biddle WP; Wurdeman RL; Mooss AN; Cichowski E; Hilleman DE
    Am Heart J; 2003 Dec; 146(6):E23. PubMed ID: 14661012
    [TBL] [Abstract][Full Text] [Related]  

  • 56. N-acetylcysteine in critically ill patients undergoing contrast-enhanced computed tomography: a randomized trial.
    Burns KE; Priestap F; Martin C
    Clin Nephrol; 2010 Oct; 74(4):323-6. PubMed ID: 20875388
    [No Abstract]   [Full Text] [Related]  

  • 57. Did contrast nephropathyin RAPPID really occur?
    DiDomenico RJ; Eyrich HM
    J Am Coll Cardiol; 2003 Dec; 42(12):2167; author reply 2167-9. PubMed ID: 14680745
    [No Abstract]   [Full Text] [Related]  

  • 58. [Drug induced nephropathy and appropriate use of drugs].
    Hirata S; Kadowaki D; Narita Y
    Nihon Jinzo Gakkai Shi; 2012; 54(7):999-1005. PubMed ID: 23234211
    [No Abstract]   [Full Text] [Related]  

  • 59. Hyperthyroidism and N-Acetylcysteine.
    Rao S; Rao S
    J Am Med Dir Assoc; 2021 Mar; 22(3):B6-B7. PubMed ID: 34287184
    [No Abstract]   [Full Text] [Related]  

  • 60. [Can the nephroprotective effect of N-acetylcysteine be optimized?].
    Barrios V; Escobar C; Echarri R
    Rev Esp Cardiol; 2010 Apr; 63(4):501-2. PubMed ID: 20334824
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.